Short review – Management of Immune Thrombocytopenia in adults
In recent years clinical management of Immune Thrombocytopenia (ITP) has clearly changed due to the emergence of new therapeutics such as Thrombopoietin Receptor Agonists or Rituximab. These agents have been tested in phase III randomized controlled trials and thereby initiated an impulse for the whole field of ITP. Moreover, in 2009 various publications systematically reviewed current practice, presented efforts of standardization as well as new guidelines for diagnosis and treatment of ITP. This short review is intended to summarize these new developments and to propose an up-dated treatment algorithm.